This Article  • Full text  • PDF  • CME Course for This Article  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Nutritional and Metabolic Disorders  • Nutritional and Metabolic Disorders, Other  • Diabetic Retinopathy  • Prognosis/ Outcomes  • Articles for Residents  • Drug Therapy  • Drug Therapy, Other  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

10 Years After the Diabetes Control and Complications Trial

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group^*

Arch Ophthalmol. 2008;126(12):1707-1715.

Objective  To examine the persistence of the original treatment effects 10 years after the Diabetes Control and Complications Trial (DCCT) in the follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study. In the DCCT, intensive therapy aimed at near-normal glycemia reduced the risk of microvascular complications of type 1 diabetes mellitus compared with conventional therapy.

Methods  Retinopathy was evaluated by fundus photography in 1211 subjects at EDIC year 10. Further 3-step progression on the Early Treatment Diabetic Retinopathy Study scale from DCCT closeout was the primary outcome.

Results  After 10 years of EDIC follow-up, there was no significant difference in mean glycated hemoglobin levels (8.07% vs 7.98%) between the original treatment groups. Nevertheless, compared with the former conventional treatment group, the former intensive group had significantly lower incidences from DCCT close of further retinopathy progression and proliferative retinopathy or worse (hazard reductions, 53%-56%; P < .001). The risk (hazard) reductions at 10 years of EDIC were attenuated compared with the 70% to 71% over the first 4 years of EDIC (P < .001). The persistent beneficial effects of former intensive therapy were largely explained by the difference in glycated hemoglobin levels during DCCT.

Conclusion  The persistent difference in diabetic retinopathy between former intensive and conventional therapy ("metabolic memory") continues for at least 10 years but may be waning.

Trial Registration  clinicaltrials.gov Identifiers: NCT00360815 and NCT00360893.

*Authors/Group Information: A complete listing of the authors and Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group and their affiliations appears in the Author Information section.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Metabolic Memory in the Autonomic Neuropathy of Diabetes: Implications for Pathogenesis and Patient Care
Chaturvedi
Circulation 2009;119:2865-2867.
FULL TEXT  

Progress in Diabetes Research--What's Next
Nathan
JAMA 2009;301:1599-1601.
FULL TEXT  

Metabolic Memory in Diabetes Is True Long-term Memory
Frank
Arch Ophthalmol 2009;127:330-331.
FULL TEXT